ACTIV-3 trial planned to investigate safety and efficacy of ensovibep in adults hospitalized with a COVID-19 diagnosis; first patient dose expected in Q2 2021 Ensovibep to be first non-antibody therapeutic assessed in ACTIV-3 Clinical trial includes an interim analysis after 300 patients

Acknowledged innovation leader with deep scientific and business expertise in immunotherapy, oncology and infectious diseases Zurich-Schlieren, Switzerland, March 11, 2021.   Molecular Partners AG  (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein

Zurich-Schlieren, Switzerland, March 10, 2021.   Molecular Partners AG  (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today   announced the upcoming presentation of four posters with data supporting three of

Initial findings show ensovibep to be safe and well tolerated with no significant adverse events Predictable exposure seen post administration, confirming the expected half-life of 2‑3 weeks Global phase 2/3 registrational study planned to initiate in Q2 2021 Zurich-Schlieren, Switzerland, March

Zurich-Schlieren, Switzerland, February 26, 2021.   Molecular Partners AG  (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today published its audited Financial Results for 2020 and the company’s 2020 Annual Report.

Event:  Leerink 10th Annual Global Healthcare Conference Date/Time:  Thursday, February 25, 8:40 AM – 9:10 AM ET (2:40 PM – 3:10 PM CET)   Event:  Cowen 41st Annual Health Care Conference Date/Time:  Tuesday, March 2, 2021, 10:30 AM – 11:00 AM ET (4:30 PM – 5:00 PM CET)   Event:  H.C.

Research & Development Highlights: Virology: Initiated and rapidly advanced COVID-19 antiviral program into the clinic; secured collaboration with Novartis for co-development of multi-specific candidates MP0420 (ensovibep) and MP0423, including options for global commercialization; terms included

New study shows that Molecular Partners’ tri-specific antiviral DARPin® candidates,  ensovibep ( MP0420) and the Company’s preclinical candidate, MP0423, remain therapeutically active against the known mutations of SARS-CoV-2 including those present in the United Kingdom (UK) and South Africa (SA)

Zurich-Schlieren, Switzerland, January 06, 2021.   Molecular Partners AG  (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will present at or

First-in-human data from ongoing phase 1 study of MP0310 (AMG 506) demonstrate encouraging biological activity, including successful localized tumor engagement and saturation Data from ongoing phase 1 COVID-19 study show that MP0420 (ensovibep) is well tolerated in first dose cohort Unique